REG - GSK PLC - Director/PDMR Shareholding
15/04/2024 15:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240415:nRSO6703Ka&default-theme=true
RNS Number : 6703K GSK PLC 15 April 2024
GSK plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 8 (partnership shares)
£16.1277 8 (matching shares)
d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Julie Brown
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 7 (partnership shares)
£16.1277 7 (matching shares)
d) Aggregated information
Aggregated volume Price 14 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 7 (partnership shares)
£16.1277 7 (matching shares)
d) Aggregated information
Aggregated volume Price 14 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 8 (partnership shares)
£16.1277 8 (matching shares)
d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 7 (partnership shares)
£16.1277 7 (matching shares)
d) Aggregated information
Aggregated volume Price 14 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 8 (partnership shares)
£16.1277 8 (matching shares)
d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 8 (partnership shares)
£16.1277 8 (matching shares)
d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 8 (partnership shares)
£16.1277 8 (matching shares)
d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.1277 8 (partnership shares)
£16.1277 8 (matching shares)
d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.1277
e) Date of the transaction 2024-04-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 24
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 4
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 7
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 58
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 3
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 69
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 25
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 43
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 56
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3094 53
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dylan Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.2891 24
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
£16.2891 16
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Iain Whyte
b) Position/status PCA of Ms V Whyte (Company Secretary)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.2891 1090
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status Chief Strategy Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024, on Ordinary Shares held within an ISA
c) Price(s) and volume(s) Price(s) Volume(s)
£15.3860 19
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 11 April 2024, on Ordinary Shares held within an ISA
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3860 16
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Elizabeth McKee Anderson
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
$40.9550 11
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Charles Bancroft
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
$40.9550 68
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Hal Barron
b) Position/status Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
$40.9550 13
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Anne Beal
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
$40.9550 9
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Harry Dietz
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
$40.9550 9
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Jesse Goodman
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
$40.9550 9
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Vishal Sikka
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 11 April 2024
c) Price(s) and volume(s) Price(s) Volume(s)
$40.9550 43
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-04-12
f) Place of the transaction New York Stock Exchange (XNYS)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFSFLIELSESLRecent news on GSK
See all newsREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK announces additional EAGLE-1 results
AnnouncementREG - GSK PLC - Results from long-term data relating to Shingrix
Announcement